Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Irene Hamrick MD, FAAFP, AGSF, CMD
Irene Hamrick MD, FAAFP, AGSF, CMD Advisory Board
Jonathan Temte MD, PhD
Jonathan Temte MD, PhD Advisory Board
David Rakel MD, FAAFP
David Rakel MD, FAAFP Editor-in-Chief
See All Experts
featured
Published in Primary Care and
1 other channel

Journal Scan / Research · May 25, 2017

Evacetrapib Does Not Reduce Cardiovascular Risk in High-Risk Vascular Disease

The New England Journal of Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Christopher Cannon MD

The New England Journal of Medicine
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
N. Engl. J. Med 2017 May 18;376(20)1933-1942, AM Lincoff, SJ Nicholls, JS Riesmeyer, PJ Barter, HB Brewer, KAA Fox, CM Gibson, C Granger, V Menon, G Montalescot, D Rader, AR Tall, E McErlean, K Wolski, G Ruotolo, B Vangerow, G Weerakkody, SG Goodman, D Conde, DK McGuire, JC Nicolau, JL Leiva-Pons, Y Pesant, W Li, D Kandath, S Kouz, N Tahirkheli, D Mason, SE Nissen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated